Literature DB >> 19190976

Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.

Christine Y Lu1.   

Abstract

The topic of drug safety has received great attention in recent years. Pharmacoepidemiology is the study of the use and effects of medicines in large populations using epidemiological methods. Pharmacoepidemiologic research can fill the knowledge gaps due to the limitations of existing pharmacovigilance systems that rely on randomised controlled trials and voluntary reporting. This review discusses the present state of pharmacoepidemiologic research in Australia. In Australia, linking administrative data on use of medications and medical services is possible to a certain extent. Data from patient registries with respect to rheumatology are also available. These data are valuable for better understanding of the beneficial and adverse effects of medicines. Opportunities and challenges of using these data sources to address issues from clinical pharmacology are also highlighted. Australia is well-placed internationally to make major contributions to the knowledge base of outcomes of medicines in the real-world setting. Developments in pharmacoepidemiology are critical to clinicians treating patients with rheumatic and other conditions.

Entities:  

Mesh:

Year:  2009        PMID: 19190976     DOI: 10.1007/s10067-009-1102-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  47 in total

1.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

Authors:  T Brewer; G A Colditz
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

2.  Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.

Authors:  D J Edmonds; D M Dumbrell; J G Primrose; P McManus; D J Birkett; V Demirian
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

3.  Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?

Authors:  C Y Lu; K M Williams; R O Day
Journal:  Intern Med J       Date:  2007-06-02       Impact factor: 2.048

4.  Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans.

Authors:  Elizabeth E Roughead; Brian McDermott; Andrew L Gilbert
Journal:  Aust N Z J Psychiatry       Date:  2007-04       Impact factor: 5.744

Review 5.  Evaluating medicines: let's use all the evidence.

Authors:  Chris W Kelman; Sallie-Anne Pearson; Richard O Day; C D'Arcy J Holman; Erich V Kliewer; David A Henry
Journal:  Med J Aust       Date:  2007-03-05       Impact factor: 7.738

6.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

7.  Ovarian cancer in Western Australia (1982-1998): trends in surgical intervention and relative survival.

Authors:  Crystal L Laurvick; James B Semmens; Yee C Leung; C D'Arcy J Holman
Journal:  Gynecol Oncol       Date:  2003-02       Impact factor: 5.482

8.  Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.

Authors:  Susanne Oksbjerg Dalton; Christoffer Johansen; Lene Mellemkjaer; Bente Nørgård; Henrik Toft Sørensen; Jørgen H Olsen
Journal:  Arch Intern Med       Date:  2003-01-13

9.  Recall accuracy for prescription medications: self-report compared with database information.

Authors:  S L West; D A Savitz; G Koch; B L Strom; H A Guess; A Hartzema
Journal:  Am J Epidemiol       Date:  1995-11-15       Impact factor: 4.897

10.  The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.

Authors:  Christine Y Lu; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2007-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.